Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 26;4(1):ofw258. doi: 10.1093/ofid/ofw258

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2016. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

PMC Copyright notice

Figure 2. — Achievement of SVR12. ^aSustained virologic response 12 weeks after the end of treatment (SVR12) analysis was based on a snapshot approach. ^bIncludes 7 patients treated with simeprevir + peginterferon + ribavirin. ^cExcludes 1 patient who completed treatment and the study but was missing data for the SVR12 time point. ^dIncludes 6 patients treated with simeprevir + peginterferon + ribavirin. ^eThe modified intent-to-treat (mITT) population includes patients in the intent-to-treat (ITT) population excluding those who discontinued for nonvirologic reasons before the SVR12 time point, or with missing SVR12 assessment data (38 patients and 1 patient, respectively). CI, confidence interval.